Evaxion Biotech (EVAX) said Thursday it has dosed the first patient in the one-year extension of the phase 2 trial of its personalized cancer vaccine EVX-01.
The extension further evaluates the potential of the vaccine as a potential treatment for advanced melanoma, or skin cancer, particularly its long-term clinical and immune benefits, the company said.
In the first two years of the trial, the vaccine was administered in combination with standard anti-PD-1 therapy. Patients entering the extension will receive two additional EVX-1 doses as monotherapy, and results could position the vaccine as a potential standalone treatment for the disease, Evaxion said.
The trial remains on track to yield two-year data to be presented in H2, the company said.
Evaxion Biotech shares were 3.5% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.